Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What next after infliximab?

Leonard Baidoo, Gary R Lichtenstein

    The American Journal of Gastroenterology
    |January 19, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Antibodies to infliximab (ATI) can cause infusion reactions and loss of efficacy in Crohn's disease patients. Alternative therapies like adalimumab are being investigated for patients who lose response to infliximab.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Therapeutic Approaches for Disorders of Gut-Brain Interaction Other Than Medication.

    Gastroenterology & hepatology·2026
    Same author

    Update on the Management of Pregnant Patients With Inflammatory Bowel Disease.

    Gastroenterology & hepatology·2026
    Same author

    Safety and feasibility of same-day discharge after peroral endoscopic myotomy in esophageal motility disorders: a systematic review and meta-analysis.

    Surgical endoscopy·2026
    Same author

    Solitary polypoid ganglioneuroma of the sigmoid colon: A rare colonic neoplasia.

    JAAPA : official journal of the American Academy of Physician Assistants·2026
    Same author

    Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

    The American journal of gastroenterology·2026
    Same author

    Nutritional Management of Adult Patients Who Have Crohn's Disease.

    Gastroenterology & hepatology·2026
    Same journal

    Calendar of Courses, Symposiums and Conferences.

    The American journal of gastroenterology·2026
    Same journal

    Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

    The American journal of gastroenterology·2026
    Same journal

    ACG Clinical Guideline: Colonic Diverticulitis.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    2026 CME Information.

    The American journal of gastroenterology·2026
    See all related articles

    Area of Science:

    • Immunology
    • Gastroenterology
    • Pharmacology

    Background:

    • Infliximab is a biologic therapy for Crohn's disease (CD) that can induce anti-drug antibodies (ATI).
    • ATI are associated with infusion reactions and loss of infliximab efficacy in a subset of CD patients.
    • The mechanisms underlying infliximab non-response are debated, potentially involving other cytokines or beneficial autoimmunity.

    Discussion:

    • The immunogenicity of infliximab, a chimeric antibody, can lead to ATI formation.
    • While humanized and fully human antibodies aim to reduce immunogenicity, they can still elicit an immune response.
    • Loss of efficacy may be linked to ATI or other factors, including the immune system's response to neutralized TNF-alpha.

    Key Insights:

    • Antibodies to infliximab (ATI) are a significant concern in Crohn's disease treatment.

    Related Experiment Videos

  • ATI can manifest as infusion reactions or a diminished therapeutic response over time.
  • Understanding these immune responses is crucial for managing infliximab therapy.

    • Outlook:

    • Investigating alternative therapies like adalimumab for CD patients experiencing infliximab intolerance or loss of response.
    • Further research into the role of "beneficial autoimmunity" in immune-mediated diseases like Crohn's.
    • Developing strategies to mitigate immunogenicity and improve long-term efficacy of biologic therapies for inflammatory conditions.